<DOC>
	<DOC>NCT02453386</DOC>
	<brief_summary>Phase 3, international, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 3-arm safety and efficacy study (Part A) with an open-label phase (Part B).</brief_summary>
	<brief_title>Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients Using Levodopa</brief_title>
	<detailed_description>During Part A, each patient will participate for up to 30 weeks, which includes a Screening Period of 1 to ≤ 6 weeks, followed by a Baseline Visit and 24 weeks of double-blind treatment: - Screening Period: 1 - 6 weeks. - Double-Blind Treatment Period: 24 weeks. After completion of Part A, patients will continue in Part B for an additional 56 weeks: - Open-Label Treatment Period: 52 weeks. - Post-Treatment Safety Follow Up: 4 weeks.</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Patient understands study requirements and has given his/her written informed consent on an Institutional Review Board (IRB) or Independent Ethics Committee (IEC) approved consent form. Parkinson's disease diagnosis consistent with UK Parkinson's Disease Society Brain Bank Diagnostic criteria Minimum of 3 years since diagnosis. Meet Hoehn and Yahr PD stage Good response to levodopa Stable regimen of antiPD medications Patients must have been taking a levodopacontaining antiPD medication continuously for at least the previous 12 months Patient has documented a minimum amount of Off time. If of childbearing potential (male and female) must use an acceptable method of contraception Previous tozadenant study participation Current or recent participation in another study. Secondary or atypical parkinsonism Neurosurgical intervention for PD Patient is taking apomorphine, budipine, istradefylline, tolcapone, or DUOPA™/Duodopa® Treatment with excluded medications Untreated or uncontrolled hyperthyroidism or hypothyroidism Clinically significant outofrange laboratory MMSE out of range Current episode of major depression (stable treatment for depression is permitted). Recent suicide attempt or suicidal ideation type 4 or type 5 of the ColumbiaSuicide Severity Rating Scale (CSSRS) Women lactating or pregnant Hypersensitivity to any components of tozadenant or excipients Abnormal findings on the physical or neurological examination, or medical history that would make the patient unsuitable for the study History of hepatitis or cholangitis</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Motor fluctuations</keyword>
	<keyword>Off time</keyword>
	<keyword>On time</keyword>
	<keyword>Dyskinesia</keyword>
</DOC>